Literature DB >> 15667972

Radiotherapy for local control of osteosarcoma.

Thomas F DeLaney1, Lily Park, Saveli I Goldberg, Eugen B Hug, Norbert J Liebsch, John E Munzenrider, Herman D Suit.   

Abstract

PURPOSE: Local control of osteosarcoma in patients for whom a resection with satisfactory margins is not achieved can be difficult. This study evaluated the efficacy of radiotherapy (RT) in this setting. METHODS AND MATERIALS: We identified 41 patients in our sarcoma database with osteosarcomas that either were not resected or were excised with close or positive margins and who underwent RT with external beam photons and/or protons at our institution between 1980 and 2002. Patient charts were reviewed to assess local control, progression-free survival, metastasis-free survival, and overall survival.
RESULTS: The anatomic sites treated were head/face/skull in 17, extremity in 8, spine in 8, pelvis in 7, and trunk in 1. Of the 41 patients, 27 (65.85%) had undergone gross total tumor resection, 9 (21.95%) subtotal resection, and 5 (12.2%) biopsy only. The radiation dose ranged from 10 to 80 Gy (median 66). Twenty-three patients (56.1%) received a portion of their RT with protons. Chemotherapy was given to 35 patients (85.4%). Of the 41 patients, 27 (65.85%) were treated for localized disease at primary presentation, 10 (24.4%) for local recurrence, and 4 (9.8%) for metastatic disease. The overall local control rate at 5 years was 68% +/- 8.3%. The local control rate according to the extent of resection was 78.4% +/- 8.6% for gross total resection 77.8% +/- 13.9% for subtotal resection, and 40% +/- 21.9% for biopsy only (p < 0.01). The overall survival rate according to the extent of resection was 74.45% +/- 9.1% for gross total resection, 74.1% +/- 16.1% for subtotal resection, and 25% +/- 21.65% for biopsy only (p < 0.001). Patients with either gross or subtotal resection had a greater rate of local control, survival, and disease-free survival compared with those who underwent biopsy only at 5 years (77.7% +/- 7.5% vs. 40% +/- 21% [p <0.001], 73.9% +/- 8.1% vs. 25% +/- 21.6% [p <0.001], and 51.9% +/- 9.1% vs. 25% +/- 21.6% [p <0.01], respectively). Overall survival was better in patients treated at primary presentation (78.8% +/- 8.6% compared with 54% +/- 17.3% for recurrence) p <0.05). No definitive dose-response relationship for local control of tumor was seen, although the local control rate was 71% +/- 9% for 32 patients receiving doses > or =55 Gy vs. 53.6% +/- 20.1% for 9 patients receiving <55 Gy (p = 0.11). Of 15 patients with tumors >5.3 cm, 9 received doses > or =55 Gy and the local control rate was 80% +/- 17.9%, and 6 received doses <55 Gy with a local control rate of only 50% +/- 25% at 5 years (p = 0.16). Among patients who underwent gross total resection, the local control rate was 77.5% +/- 9.95% in 22 patients with negative margins vs 66.7% +/- 27.2% in 3 patients with positive margins (p = 0.54). Two patients had unknown margin status.
CONCLUSION: RT can help provide local control of osteosarcoma for patients in whom surgical resection with widely, negative margins is not possible. It appears to be more effective in situations in which microscopic or minimal residual disease is being treated.

Entities:  

Mesh:

Year:  2005        PMID: 15667972     DOI: 10.1016/j.ijrobp.2004.05.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  62 in total

Review 1.  Novel therapeutic approaches in pediatric and young adult sarcomas.

Authors:  Peter M Anderson; Margaret Pearson
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 2.  Multidisciplinary management of primary tumors of the vertebral column.

Authors:  Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2009-06-23

Review 3.  Clinical effectiveness of Enneking appropriate versus Enneking inappropriate procedure in patients with primary osteosarcoma of the spine: a systematic review with meta-analysis.

Authors:  Bruno Pombo; Ana Cristina Ferreira; Pedro Cardoso; António Oliveira
Journal:  Eur Spine J       Date:  2019-08-13       Impact factor: 3.134

4.  Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow.

Authors:  Wei Zhang; Masato Tanaka; Yoshihisa Sugimoto; Tomoyuki Takigawa; Toshifumi Ozaki
Journal:  Eur Spine J       Date:  2015-08-23       Impact factor: 3.134

Review 5.  State-of-the-art approach for bone sarcomas.

Authors:  Andreas F Mavrogenis; Andrea Angelini; Christos Vottis; Emanuela Palmerini; Eugenio Rimondi; Giuseppe Rossi; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-05-03

6.  Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck.

Authors:  Stanley I Gutiontov; Zachary S Zumsteg; Benjamin H Lok; Sean Berry; Chiaojung J Tsai; Sean M McBride; Nadeem Riaz; Oren Cahlon; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2017-03-14

Review 7.  Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives.

Authors:  Pete Anderson; Maritza Salazar-Abshire
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

Review 8.  How Technology Is Improving the Multidisciplinary Care of Sarcoma.

Authors:  Inga-Marie Schaefer; Kelvin Hong; Anusha Kalbasi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

9.  Molecular mechanisms underlying the enhancement of carbon ion beam radiosensitivity of osteosarcoma cells by miR-29b.

Authors:  Eun Ho Kim; Jeong Yub Kim; Mi-Sook Kim; Guillaume Vares; Tatsuya Ohno; Akihisa Takahashi; Akiko Uzawa; Seung-Jun Seo; Sei Sai
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 10.  The multidisciplinary management of osteosarcoma.

Authors:  Noah Federman; Nicholas Bernthal; Fritz C Eilber; William D Tap
Journal:  Curr Treat Options Oncol       Date:  2009-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.